Statera Biopharma Inc
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells an… Read more
Statera Biopharma Inc (STAB) - Net Assets
Latest net assets as of September 2022: $-10.17 Million USD
Based on the latest financial reports, Statera Biopharma Inc (STAB) has net assets worth $-10.17 Million USD as of September 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.75 Million) and total liabilities ($22.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-10.17 Million |
| % of Total Assets | -79.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | -141.69% |
| 10-Year Change | -100.1% |
| Growth Volatility | 53.83 |
Statera Biopharma Inc - Net Assets Trend (2012–2022)
This chart illustrates how Statera Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Statera Biopharma Inc (2012–2022)
The table below shows the annual net assets of Statera Biopharma Inc from 2012 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-1.51 Million | 0.00% |
| 2021-12-31 | $-1.51 Million | +58.78% |
| 2020-12-31 | $-3.66 Million | -140.68% |
| 2019-12-31 | $-1.52 Million | -142.03% |
| 2018-12-31 | $3.61 Million | -51.22% |
| 2017-12-31 | $7.41 Million | -42.33% |
| 2016-12-31 | $12.85 Million | -14.57% |
| 2015-12-31 | $15.04 Million | +101.50% |
| 2014-12-31 | $-1.00 Billion | -163.49% |
| 2013-12-31 | $1.58 Billion | -92.28% |
| 2012-12-31 | $20.49 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Statera Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11670623100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $177.42K | % |
| Other Comprehensive Income | $-6.65K | % |
| Other Components | $127.74 Million | % |
| Total Equity | $-1.57 Million | 100.00% |
Statera Biopharma Inc Competitors by Market Cap
The table below lists competitors of Statera Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SKYCITY ENTERT
BE:RX4
|
$4.82K |
|
Avalanche International Corp
PINK:AVLP
|
$4.82K |
|
YUEXIU TRANSPOR (GZ3.SG)
STU:GZ3
|
$4.82K |
|
EFG Holding
EGX:HRHO
|
$4.82K |
|
INDORAMA VEN -F-
MU:I93
|
$4.80K |
|
WGHT WTCHER INTL (WW6.SG)
STU:WW6
|
$4.80K |
|
OAB Anlagen und Osnabrucker Beteiligungs AG
HM:OAB
|
$4.79K |
|
Lloyds Enterprises Limited
NSE:LLOYDSENT
|
$4.79K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Statera Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -1,568,038 to -1,568,038, a change of 0.
- Net loss of 174,408,164 reduced equity.
- Other comprehensive income decreased equity by 6,651.
- Other factors increased equity by 174,414,815.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-174.41 Million | -11122.7% |
| Other Comprehensive Income | $-6.65K | -0.42% |
| Other Changes | $174.41 Million | +11123.12% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Statera Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.47 | $0.00 | x |
| 2007-12-31 | $1.13 | $0.00 | x |
| 2008-12-31 | $39.56 | $0.00 | x |
| 2009-12-31 | $-355.10 | $0.00 | x |
| 2010-12-31 | $-559.69 | $0.00 | x |
| 2012-12-31 | $156.94 | $0.00 | x |
| 2013-12-31 | $-200.42 | $0.00 | x |
| 2014-12-31 | $-0.37 | $0.00 | x |
| 2015-12-31 | $1.40 | $0.00 | x |
| 2016-12-31 | $0.68 | $0.00 | x |
| 2017-12-31 | $0.20 | $0.00 | x |
| 2018-12-31 | $-0.13 | $0.00 | x |
| 2019-12-31 | $-0.16 | $0.00 | x |
| 2020-12-31 | $-0.14 | $0.00 | x |
| 2021-12-31 | $-0.04 | $0.00 | x |
| 2022-12-31 | $-0.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Statera Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11728.58%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-238.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -129.13% | -422.82% | 0.00x | 0.00x | $-7.78 Million |
| 2007 | -190.19% | -1337.42% | 0.00x | 0.00x | $-28.42 Million |
| 2008 | -2605.79% | 0.00% | 0.00x | 0.00x | $-14.08 Billion |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.15 Billion |
| 2010 | 0.00% | -89.40% | 0.00x | 0.00x | $1.56 Billion |
| 2012 | -287.92% | 0.00% | 0.00x | 5.05x | $-18.87 Billion |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.31 Billion |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $1.73 Billion |
| 2015 | -127.81% | 0.00% | 0.00x | 2.11x | $-13.63 Million |
| 2016 | -35.34% | 0.00% | 0.00x | 2.12x | $-3.41 Million |
| 2017 | -441.26% | 0.00% | 0.00x | 4.38x | $-9.93 Million |
| 2018 | 0.00% | -47.58% | 1.67x | 0.00x | $-3.47 Million |
| 2019 | 0.00% | -7.11% | 28527.88x | 0.00x | $-2.93 Million |
| 2020 | 0.00% | -31.83% | 40.13x | 0.00x | $-12.86 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-101.69 Million |
| 2022 | 0.00% | -11728.58% | 0.07x | 0.00x | $-174.25 Million |
Industry Comparison
This section compares Statera Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Statera Biopharma Inc (STAB) | $-10.17 Million | -129.13% | N/A | $4.81K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |